Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (4175)	2/24/1998 12:09:00 AM
From: Rocketman	Read Replies (2) \| Respond to of 9719

I only passed it on as it scanned, with corrections for OCR mistakes. Yeah he did really say that. I've also got a copy of the Nature Biotechnology analysis by Harry Meade and Carol Ziomek of GZTC, but I haven't read it yet and since the font is smaller, the article a lot longer, and the copy mediocre haven't tried scanning it in and correcting it yet. It looks more onerous. Based on a quick skim of the analysis, the basic gist is that they think that milk production provides a better yield in g/l and hence a lower cost by many fold than peepro. But, each system could possibly have its advantages. From an investor in public stocks angle, piss on the piss, and suck down on the teats - GO GZTC GO!!! Rman